Study record · Survodutide
Survodutide for obesity: randomized Phase 2 dose-finding trial
Mean weight changes were approximately -6.2%, -12.5%, -13.2% and -14.9% across ascending doses vs -2.8% placebo.
Key result
Mean weight changes were approximately -6.2%, -12.5%, -13.2% and -14.9% across ascending doses vs -2.8% placebo.
Study details
Study designRandomized, double-blind, placebo-controlled dose-finding trial
PhasePhase 2
PopulationAdults with overweight or obesity
Sample size387
RouteSubcutaneous
Regimen / exposure0.6, 2.4, 3.6 or 4.8 mg once weekly with escalation
Duration46 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change
Safety resultGI adverse events were frequent and were a major tolerability limitation.
Key limitationsPhase 2 size/duration; dose escalation and discontinuations affect estimands; no long-term outcomes.
Registry / identifierPhase 2 obesity trial